MedTrace Logo

Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia

NCT03896971 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2021-09-29

No results posted yet for this study

Summary

To the investigator's Knowledge this is the first study that will assess Treatment with thrombopoietin Mimetic plus immunosuppressiveTherapy in Egyptian Patients with Aplastic Anaemia.

Aim of the work :

1. To evaluate the efficacy, tolerability and toxicity of the combination of thrombopoietin mimetic and immunosuppressive therapy in Egyptian patients with AA.
2. To study the influence of this combination on patients' quality of life.
3. To access evolution to paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome , acute leukemia or development of fibrosis

Conditions

  • Aplastic Anemia

Interventions

DRUG

Combination of thrombopoietin mimetic and cyclosporin A

This is a controlled interventional study that will be carried out in the Clinical Hematology Unit, at the Department of Internal Medicine , Assiut University Hospital. Patients will be recruited among those who attending the outpatient clinic or admitted in the unit.

Sponsors & Collaborators

  • Assiut University

    collaborator OTHER

  • Safaa AA Khaled

    lead OTHER

Principal Investigators

  • Safinaz Hussien, MD · Assiut University

  • Sawsan A Abdelaal, M.B.B.Ch · Assiut University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-15
Primary Completion
2020-12-01
Completion
2021-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03896971 on ClinicalTrials.gov